

SEATTLE CHILDREN'S HOSPITAL

Department of Pediatric Neurology — Gene Therapy Program
4800 Sand Point Way NE | Seattle, WA 98105

GENE THERAPY TREATMENT RECORD

Patient:	Aiden Foster
DOB:	2022-03-10
MRN:	AIDEN_F
Therapy:	Onasemnogene abeparvovec-xioi (Zolgensma)
Administration Date:	2023-02-20
Age at Administration:	11 months
Dose:	1.1 x 10 ¹⁴ vg/kg, single IV infusion
Administering Facility:	Seattle Children's Hospital

TREATMENT OUTCOME

Initial stabilization of motor function for approximately 12 months. HFMSE improved from 14 to 24 in first year post-treatment. However, motor function has been declining over past 12 months (HFMSE now 18), suggesting gene therapy effect may be waning.

ANTI-AAV9 ANTIBODY STATUS

Positive (titer 1:102,400) — precludes re-dosing with Zolgensma

Electronically signed by: Dr. Amanda Liu, MD | Seattle Children's Hospital